Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

SML0422

Sigma-Aldrich

Istradefylline

≥98% (HPLC)

Sinónimos:

(E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine, 8-[(1E)-2-(3,4-Dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione, KW-6002

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C20H24N4O4
Número de CAS:
155270-99-8
Peso molecular:
384.43
Número MDL:
MFCD00928421
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
329825417
NACRES:
NA.77

Nivel de calidad

100

Ensayo

≥98% (HPLC)

Formulario

powder

color

white to beige

solubilidad

DMSO: 5 mg/mL (clear solution)

temp. de almacenamiento

2-8°C

cadena SMILES

CCN1C(=O)N(CC)c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2C1=O

InChI

1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+

Clave InChI

IQVRBWUUXZMOPW-PKNBQFBNSA-N

Información sobre el gen

human ... ADORA2A(135)

Acciones bioquímicas o fisiológicas

Istradefylline (KW-6002) is a potent and selective adenosine A2A receptor selective antagonist which has been investigated for use in Parkinson′s Disease.
Istradefylline (KW-6002) is a potent and selective adenosine A2A receptor selective antagonist.

Características y beneficios

This compound is featured on the Adenosine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictogramas

Skull and crossbones
GHS06

Palabra de señalización

Danger

Frases de peligro

H301

Clasificaciones de peligro

Acute Tox. 3 Oral

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000220772
0000218350
0000218351
0000167605

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

William Knebel et al.
Journal of clinical pharmacology, 51(1), 40-52 (2010-03-05)
This model-based analysis quantifies the population pharmacokinetics (PK) of orally administered istradefylline, a selective adenosine A(2A) receptor antagonist, in healthy subjects and patients with Parkinson's disease, including the estimation of covariate effects on istradefylline PK parameters. Istradefylline plasma concentration data
Giana P Cognato et al.
Journal of neurochemistry, 112(2), 453-462 (2009-11-03)
Seizures early in life cause long-term behavioral modifications, namely long-term memory deficits in experimental animals. Since caffeine and adenosine A(2A) receptor (A(2A)R) antagonists prevent memory deficits in adult animals, we now investigated if they also prevented the long-term memory deficits
Peter Jenner
Expert opinion on investigational drugs, 14(6), 729-738 (2005-07-12)
Dopamine replacement therapy effectively treats the early motor symptoms of Parkinson's disease (PD). However, its association with the development of motor complications limits its usefulness in late stages of the disease. Adenosine A(2A) receptors are localised to the indirect striatal
H H Fernandez et al.
Parkinsonism & related disorders, 16(1), 16-20 (2009-07-21)
6002-US-051 was a 12-week, double-blind study evaluating the safety and efficacy of istradefylline, a selective A(2A) adenosine receptor antagonist, as monotherapy in patients with Parkinson's disease (PD). Patients with Hoehn-Yahr stages 1-2.5 who had not received dopaminergic drugs in the
Yoshikuni Mizuno et al.
Movement disorders : official journal of the Movement Disorder Society, 25(10), 1437-1443 (2010-07-16)
The objectives of this study were to evaluate the efficacy of istradefylline at an oral dose of 20 mg or 40 mg once daily for 12 weeks in Parkinson's disease (PD) patients with motor complications on levodopa therapy based on
Ver todos los artículos relacionados

Artículos

Adenosine Receptors

We offers many products related to adenosine receptors for your research needs.

Adenosine Receptors

We offers many products related to adenosine receptors for your research needs.

Adenosine Receptors

We offers many products related to adenosine receptors for your research needs.

Adenosine Receptors

We offers many products related to adenosine receptors for your research needs.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico